H.C. Wainwright raised the firm’s price target on Jade Biosciences (JBIO) to $45 from $35 and keeps a Buy rating on the shares. The company is set to report data from a Phase 1 study with JADE101 in healthy volunteers by the end of Q2, the analyst tells investors in a research note. H.C. Wainwright increased JADE101’s probability of success in IgAN to 40% from 33%.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JBIO:
- Jade Biosciences appoints Edward Conner as chief medical officer
- Jade Biosciences Elevates Andrew King to R&D President
- Jade Biosciences Adopts 2026 Employment Inducement Stock Plan
- Jade Biosciences price target raised to $35 from $25 at H.C. Wainwright
- Jade Biosciences participates in a conference call with William Blair